Pharmafile Logo
Pharmafocus logo
Advanced Search

selexipag

Showing 3 posts of 3 posts found.

EMA inside

Actelion’s Uptravi and rare bleeding disorder drug get positive EMA decisions

February 1, 2016
Sales and Marketing CHMP, EMA, Uptravi, pulmonary arterial hypertension, selexipag

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has issued positive opinions on …

News
Actelion logo

Actelion’s Uptravi goes on sale

January 5, 2016
Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag

Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …

News
Actelion building

Actelion ready to launch Uptravi after FDA approval

December 22, 2015
Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag

Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024